We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Fascioliasis

News List

Lasa Supergenerics adds oxyclozanide to its product portfolio expresspharma
June 10, 2021
Lasa Supergenerics, a producer of veterinary and human APIs in India has added another product – Oxyclozanide to its portfolio of products.
Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease worldpharmanews
February 19, 2019
Novartis announced that the US Food and Drug Administration (FDA) has approved Egaten® (triclabendazole) for the treatment of fascioliasis in patients six years of age and older.
FDA Approves Egaten (triclabendazole) for the Treatment of Fascioliasis, a Neglected Tropical Disease drugs
February 14, 2019
Novartis announced today that the US Food and Drug Administration (FDA) has approved Egaten (triclabendazole) for the treatment of fascioliasis in patients six years of age and older....